Pathogenesis of polycystic ovary syndrome: what is the role of obesity?
- 31 March 2004
- journal article
- review article
- Published by Elsevier in Metabolism
- Vol. 53 (3), 358-376
- https://doi.org/10.1016/j.metabol.2003.10.005
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Skeletal Muscle TriglyceridesAnnals of the New York Academy of Sciences, 2002
- Insulin Sensitizer, Troglitazone, Directly Inhibits Aromatase Activity in Human Ovarian Granulosa CellsBiochemical and Biophysical Research Communications, 2000
- Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary SyndromeNew England Journal of Medicine, 1999
- Pediatric Endocrinology Update: An OverviewHormone Research in Paediatrics, 1998
- Effect of Testosterone and Estradiol in a Man with Aromatase DeficiencyNew England Journal of Medicine, 1997
- Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndromeClinical Endocrinology, 1996
- Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary SyndromeNew England Journal of Medicine, 1996
- Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.JCI Insight, 1995
- Coronary Heart Disease Risk Factors in Women With Polycystic Ovary SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women*Clinical Endocrinology, 1993